Established data describing the optimal duration of dual antiplatelet therapy (DAPT) after endovascular therapy (EVT) for patients with peripheral artery disease (PAD) are limited. This study is a prospective, multi-center single-arm study evaluating 1-month DAPT on clinical outcomes following EVT using drug-coated balloon (DCB) for patients with symptomatic femoropopliteal artery (FPA) disease. A total of 151 patients with de novo FPA lesions which planned DCB therapy were enrolled from seven centers. DAPT (aspirin 100 mg/day and clopidogrel 75 mg/day) was started prior to EVT and continued 1-month after EVT, and subsequent aspirin monotherapy was continued during follow-up period. The primary endpoint was 1-year primary patency, as assessed by duplex ultrasound. Secondary endpoints included re-occlusion, target lesions revascularization (TLR), major amputation, acute limb ischemia (ALI), and bleeding events at one year. Mean age was 74.6 ± 8.8 and critical limb ischemia were observed in 48 patients (31.8
Background: The effectiveness of additional left atrial ablation beyond pulmonary vein isolation (PVI) for persistent atrial fibrillation (AF) remains controversial. Hypertension (HT) promotes atrial remodeling and arrhythmogenic substrate formation. The EARNEST-PVI trial demonstrated that additional left atrial ablation reduced AF recurrence after catheter ablation for persistent AF. However, whether HT modifies the effectiveness of different ablation strategies remains unclear. This study investigated the interaction between HT status and ablation strategy on AF recurrence outcomes. Methods and Results: This subanalysis of the multicentre, prospective, randomised EARNEST-PVI trial examined 497 patients undergoing their first radiofrequency catheter ablation procedure for persistent AF. The mean age was 65.0 ± 9.3 years, 376 patients (75.7%) were male and the mean left atrial diameter was 42.0 ± 4.6 mm. Patients were classified according to their HT status and randomised to receive either PVI alone (the PVI-alone group) or PVI plus additional left atrial ablation (the PVI-plus group). The primary outcome was AF recurrence after ablation. During follow-up, 127 recurrence events occurred. In patients without HT, recurrence-free survival was similar between the PVI-plus and PVI-alone groups (hazard ratio (HR) 1.00, 95% confidence interval (CI) 0.58-1.71, P = 0.987). However, in patients with HT, the PVI-plus strategy was associated with a significantly lower recurrence risk than the PVI-alone strategy (HR 0.46, 95% CI 0.29-0.75, P = 0.002). Cox proportional hazards analysis revealed a significant interaction between HT status and ablation strategy with regard to AF recurrence (P for interaction = 0.039). Procedure-related complications occurred in five patients (2.0%) in the PVI-alone group and nine patients (3.6%) in the PVI-plus group, with no significant difference between the two groups (P = 0.412). No significant interaction was observed between HT status and ablation strategy for complication outcomes (P for interaction = 0.573). Conclusions: Hypertension was found to significantly modify the relationship between treatment allocation and AF recurrence following catheter ablation. The PVI-plus group mainly demonstrated clinical benefit in patients with hypertension, suggesting that hypertension status may be an important factor when selecting an ablation strategy for AF.
Background: Tricuspid regurgitation (TR) is frequently observed in patients with atrial fibrillation (AF) and may reflect advanced atrial remodeling. Whether TR severity influences the benefit of adjunctive substrate modification during AF ablation remains unclear. Methods: We conducted a post hoc subanalysis of the randomized SUPPRESS-AF trial comparing pulmonary vein isolation (PVI) plus adjunctive low-voltage area (LVA) ablation versus PVI alone in patients with persistent AF and available LVA mapping. Patients were stratified according to baseline TR grade as mild/no TR (grade 0-1) or clinically significant TR (grade 2-4). The primary endpoint was AF recurrence after index ablation. Cox proportional hazards models were used to estimate hazard ratios (HRs). Results: Among 341 patients enrolled in the SUPPRESS-AF trial, 336 patients with available TR assessment were included in this analysis. The mean age was 74.3 years, 49.1% were female, and mean left atrial diameter was 43.8 mm. Among them, 166 had TR grade 0-1 and 170 had TR grade 2-4. Among patients with TR grade 2-4, adjunctive LVA ablation was associated with a lower risk of AF recurrence compared with PVI alone (HR 0.60, 95% CI 0.36-0.99, P=0.044). In contrast, no significant benefit was observed in those with TR grade 0-1 (HR 0.88, 95% CI 0.56-1.37, P=0.56). TR severity showed a weak but significant positive correlation with LVA burden (Spearman rho=0.14, P=0.009). There were no significant differences in complication rates between the treatment groups. Conclusions: Adjunctive LVA ablation was associated with a lower risk of AF recurrence in patients with clinically significant TR but not in those with mild or no TR. The observed association between TR severity and LVA burden suggests that TR may reflect advanced atrial substrate remodeling and may help identify patients who could potentially benefit from adjunctive substrate modification.
Background Female sex has been associated with poor prognosis in hypertrophic cardiomyopathy (HCM), but the factors contributing to this disparity remain insufficiently defined. We aimed to clarify sex differences in clinical characteristics and factors associated with cardiovascular death in Japan. Methods This multicenter, retrospective observational study of HCM was conducted between January 1, 2006, and December 31, 2018 (REVEAL‐HCM study [Multicenter Registry to Evaluate Risk Factors for Disease Progression, Sudden Cardiac Death and Adverse Clinical Outcomes in Japanese Patients With Hypertrophic Cardiomyopathy]; UMIN000046932). Patients aged ≥16 years with HCM were enrolled. Baseline characteristics and clinical outcomes including cardiovascular death were assessed. Univariable and multivariable Cox proportional hazards models were used to identify factors associated with cardiovascular death. Results Of 3247 patients (median age, 67 years; 43% women), women were older and more symptomatic at presentation (52% New York Heart Association class II–IV versus 35% in men). Cardiovascular death was more common in women (hazard ratio [HR], 1.37 [95% CI, 1.02–1.82]; P=0.03). In multivariable analysis, older age (per 1‐year increase; HR, 1.04 [95% CI, 1.02–1.06]), advanced New York Heart Association class (HR, 1.99 [95% CI, 1.40–2.82]), history of atrial fibrillation (HR, 1.55 [95% CI, 1.10–2.18]), greater maximal wall thickness indexed to body surface area (per 1‐mm/m2 increase; HR, 1.12 [95% CI, 1.06–1.20]), and apical HCM (HR, 0.53 [95% CI, 0.32–0.88]) were independently associated with cardiovascular death, attenuating the HR for female sex. Conclusions Sex differences in clinical characteristics and outcomes were observed. The excess cardiovascular death in women with HCM was largely explained by older age, more advanced symptoms, greater indexed wall thickness, and sex‐specific differences in both the prevalence and prognostic impact of apical HCM.